吉非替尼治疗放化疗失败的晚期非小细胞肺癌38例  

Clinical effect on 38 cases of advanced non-small cell lung cancer treated with gefitinib monotherapy after failure of chemotherapy and radiotherapy

作　　者：刘素娟[1] 张延可 赵颖 

机构地区：[1]山东省邹城市人民医院肿瘤科,山东邹城273500 [2]兖州矿业集团总医院放疗科,山东邹城273500

出　　处：《世界肿瘤杂志》2008年第2期136-138,共3页Tumour Journal of the World

摘　　要：目的观察吉非替尼（Iressa）单药治疗放化疗失败的晚期非小细胞肺癌（NSCLC）的近期疗效及毒副反应。方法病人来自我院及矿区医院，2005年9月至2007年2月的38个住院和门诊病例，所有病例均为ⅢB或Ⅳ期的非小细胞肺癌，其中27例病人行放化疗综合治疗后病情都出现进展（PD）或复发转移，治疗方案为吉非替尼单药口服250mg，1次／d，直至病情进展。应用t检验进行统计分析。结果38例入选病例中，CR 1例（2．6％），PR10例（26.3％），有效率（CR＋PR）28．9％；SD14例（36．8％），疾病控制率（CR＋PR＋SD）65．8％。中位症状改善时间12d，中位症状缓解持续时间5．5mo，缓解最为明显的症状为咳嗽和疼痛。中位生存期7．9mo，中位肿瘤进展时间（TTP）为7．3mo；1a生存率39．5％。最常见的毒副作用为皮疹（52．6％）和腹泻（44．7％）。结论口服Iressa单药对于经放化疗治疗失败的晚期非小细胞肺癌，是一种有效且具有良好耐受性的治疗方案。Objective To investigate the recent efficacy and toxicity of gefitinib （Iressa） in the treatment of patients with advanced non-small cell lung cancer（NSCLC） after failure of chemotherapy and radiotherapy. Methods From Sep 2005 to Feb 2007, 38 patients with stage ⅢB or Ⅳ NSCLC were treated in our hospital and hospital in mine areas, and in these 27 cases had been given chemotherapy and radiotherapy. After ward their disease progressed or had been found recur and metastasis. Gefitinib was orally administered 250 mg daily till disease progress. Clinical data were analyzed using t test. Results Among the 38 patients, complete response （CR） and partial response （PR） were 2.6% and 26.3%, and tumor response rate （CR ＋PR） was 28.9%; Stable disease （SD） was 36.8%; The disease control rate was 65.8%; The median time of occurrence of symptom improvement wasl2 days and duration was 5.5 months; The most improved symptoms were cough and ache. Median time of time to progression （TTP） and survival were 7.3 months and 7.9 months, respectively. Survival rate at 1 year was 39.5%. The major adverse events were mild skin rash （52.6%） and diarrhea （44.7%）. Conclusions Monotherapy with gefitinib is effective and tolerable for the patients with advanced NSCLC after failure of chemotherapy and radiotherapy.

关 键 词：非小细胞肺癌 吉非替尼 靶向治疗 表皮生长因子受体 

分 类 号：R743.2[医药卫生—神经病学与精神病学] R730.53[医药卫生—临床医学]